New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 22, 2024 - The FDA approved AOP Orphan Pharmaceuticals’ Rapiblyk (landiolol), for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.
Download PDF
Return to publications
